Log on / register
Feedback | Support | My details
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW
Retrovirology 2008, 5:74
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Research    
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase
Dar MJ, Monel B, Krishnan L, Shun MC, Di Nunzio F, Helland DE, Engelman A
Retrovirology 2009, 6:94 (19 October 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
2.


Review    
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
Serrao E, Odde S, Ramkumar K, Neamati N
Retrovirology 2009, 6:25 (5 March 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]
3.


Correspondence    
HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure
van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, Dwyer DE
Retrovirology 2009, 6:12 (9 February 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]

This article is also cited by a further 1 article in PubMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.